Back to top
more

XOMA Royalty Corporation (XOMA)

(Delayed Data from NSDQ)

$34.66 USD

34.66
183,402

+0.08 (0.23%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $34.74 +0.08 (0.23%) 7:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (143 out of 243)

Industry: Medical - Biomedical and Genetics

Brokerage Reports

Research for XOMA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

XOMA Royalty Corporation [XOMA]

Reports for Purchase

Showing records 1 - 20 ( 348 total )

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 1

12/30/2025

Company Report

Pages: 7

Give a Little, Get a Lot; Takeda Relationship Yields Nine New Assets for No Cash

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 2

12/16/2025

Daily Note

Pages: 4

Fifth Acquisition in 2025 Expanding Royalty and Milestone Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 3

12/11/2025

Company Report

Pages: 8

Unfortunate Ersodetug Miss; XOMA's Pipeline Breadth Provides Buffer; Target Down to $97

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 4

08/21/2025

Company Report

Pages: 8

Continuing Strategic Moves as Revenues Continue to Grow

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 5

08/04/2025

Company Report

Pages: 8

Busy Summer Continues; Setting Up Even More Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 6

05/28/2025

Company Report

Pages: 8

Tighter Hug on Mezagitamab Royalties; Cash Flow Opps Continue to Increase

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 7

03/28/2025

Company Report

Pages: 11

Evaluating Phase 3 Assets for Projected Future Growth and Value

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 8

03/19/2025

Company Report

Pages: 7

Maintaining Strong Cash Bolstered by Revenue Growth and Smart Shopping Moves; 2024 Results

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 9

02/25/2025

Daily Note

Pages: 5

Syndicated Deal Brings $75 Million to Boost DEB Phase 3 at Castle Creek

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 10

02/03/2025

Company Report

Pages: 5

Broad Portfolios for Long Term Net Positives; Price Target Adjusted Down to $104

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 11

01/07/2025

Daily Note

Pages: 5

BTD for CHI; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 12

12/13/2024

Company Report

Pages: 14

Partners'' News: More Royalties Now and Another Potential Important Stream for Intermediate Term; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 13

12/02/2024

Company Report

Pages: 12

Post-Turkey Day Late-Stage Bolt-On; Target Upped to $123

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 14

11/07/2024

Company Report

Pages: 11

3Q24 Results; Looking for Deal Creativity and Growth to Continue

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 15

10/22/2024

Daily Note

Pages: 9

Long-Term Royalty Potential Expands Significantly

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 16

09/20/2024

Daily Note

Pages: 9

Slapping Another Royalty On XOMA''s Growth Trajectory; Arimoclomol Approved

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 17

08/14/2024

Company Report

Pages: 11

Target Boosted to $117; Corporate Model and Broad Valuation Look Just Makes Sense to Us

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 18

05/31/2024

Company Report

Pages: 9

Percentage of a PRV Not Bad at All

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 19

05/01/2024

Company Report

Pages: 9

The Future Is Now as XOMA Adds More Assets Including Current Revenue Driver

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Royalty Corporation

Industry: Medical - Biomedical and Genetics

Record: 20

04/25/2024

Company Report

Pages: 8

Slap Another Royalty on That PL With OJEMDA Approval

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party